IOVANCE BIOTHERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IOVANCE BIOTHERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Feb 28, 2019 |
| FY2018 | Sep 30, 2018 | $0 | Feb 28, 2019 |
| FY2018 | Jun 30, 2018 | $0 | Feb 28, 2019 |
| FY2018 | Mar 31, 2018 | $0 | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $0 | Feb 28, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Feb 28, 2019 |
| FY2018 | Jun 30, 2017 | $0 | Feb 28, 2019 |
| FY2018 | Mar 31, 2017 | $0 | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 12, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Mar 12, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $263.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $164.07M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.19M | Feb 24, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($390.98M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($372.18M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($444.04M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($395.89M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($342.25M) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | ($68.40M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($58.57M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($63.02M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($69.60M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($63.57M) | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($403.36M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($395.28M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($460.56M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($398.88M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($342.70M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($261.94M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($206.87M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($128.26M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($92.88M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($53.64M) | Feb 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $300.27M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $276.23M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $333.19M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $294.78M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $259.04M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $201.73M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $166.02M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $99.83M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $71.62M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $26.94M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($302.41M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($352.98M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($361.82M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($292.76M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($227.94M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($205.13M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($158.89M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($101.25M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($78.71M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($32.67M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.84M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $11.07M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $22.29M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $20.43M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $37.57M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $46.79M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $6.92M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.20M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.03M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.52M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $913.17M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $910.43M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $780.35M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $663.98M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $777.33M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $768.46M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $344.66M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $480.82M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $155.37M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $171.89M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.59M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $200.02M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $195.74M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $164.34M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $155.67M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $111.96M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $45.68M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $14.63M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $9.89M | Feb 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $698.58M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $710.41M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $584.61M | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $499.64M | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $621.66M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $656.50M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $298.97M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | $466.19M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $145.48M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $166.92M | Feb 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.78B) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($2.38B) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($2.01B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.57B) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.17B) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($830.19M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($570.61M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($372.76M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($249.18M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($157.12M) | Mar 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $163.08M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $115.69M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $114.89M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $231.73M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $78.23M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $67.33M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $13.97M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $82.15M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $145.37M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $106.72M | Feb 28, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (2) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 411.94M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 305.25M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 256.14M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 187.81M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 157.00M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 147.87M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 126.41M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 123.42M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 73.16M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 62.25M | Mar 12, 2018 |